What Kaivo does differently

  1. Insulin resistance, addressed Up to 70% of women with PCOS have insulin resistance — the engine behind the weight, the belly fat, and the sugar cravings. GLP-1s lower fasting insulin and improve sensitivity, which is why they work where ordinary diets stall.
  2. Androgen and cycle screening Your starter panel includes free testosterone, DHEAS, SHBG, LH/FSH, AMH, and a fasting insulin — not just lipids and TSH. Your AIIMS-trained doctor reads the lab in PCOS context, not generic ranges.
  3. Vegetarian protein protocol PCOS plus GLP-1 plus a low-protein vegetarian diet is how you lose muscle along with fat. Our dietitians build 90–110 g/day protein plans from paneer, dal, soya, sprouts, and supplements — not ‘just eat less rice’.
  4. Fertility-aware plan GLP-1s must be stopped at least 2 months before trying to conceive. If pregnancy is on your timeline, your doctor maps a wean-and-transition plan from day one — usually to metformin or inositol — so weight loss doesn't cost you a window.
Talk to an AIIMS-trained doctor.

2-minute eligibility test. Free. We'll see if Kaivo is the right fit for you.

Why GLP-1s work for PCOS — the evidence.

Polycystic ovary syndrome affects roughly one in five Indian women of reproductive age, and the central metabolic driver in most cases is insulin resistance. Hyperinsulinaemia stimulates ovarian androgen production, suppresses sex hormone binding globulin, disrupts ovulation, and promotes visceral fat accumulation — a feedback loop that explains why ‘eat less, move more’ rarely shifts the scale for women with PCOS.

Glucagon-like peptide-1 receptor agonists target this loop in two ways. They lower fasting insulin by improving peripheral sensitivity and slowing gastric emptying, and they reduce caloric intake by signalling satiety in the hypothalamus. The net result, in studies that have specifically enrolled women with PCOS, is meaningful weight loss, restoration of regular menstrual cycles, and reductions in free testosterone.

Liraglutide in PCOS — Jensterle et al.

A 2019 randomised study in European Journal of Endocrinology by Jensterle and colleagues compared liraglutide 3.0 mg with placebo in obese women with PCOS over 12 weeks. The liraglutide group lost a mean of 5.2 kg versus 0.5 kg on placebo, with concurrent reductions in free testosterone and improvements in menstrual regularity. Subsequent work by the same group showed that combining liraglutide with metformin produced greater fat-mass loss than metformin alone, and that semaglutide (the active in Wegovy and Ozempic) outperformed liraglutide on weight endpoints in head-to-head obesity trials.

Semaglutide and metabolic markers — STEP-1

The STEP-1 trial (Wilding et al., New England Journal of Medicine 2021) — the registration trial for semaglutide 2.4 mg in obesity — enrolled 1,961 adults without diabetes and reported a mean body-weight reduction of 14.9% at 68 weeks versus 2.4% on placebo. While STEP-1 was not a PCOS-specific trial, its participants had the metabolic profile most women with PCOS share: elevated BMI, dyslipidaemia, and insulin resistance. Sub-analyses showed marked reductions in fasting insulin, HOMA-IR, and waist circumference — all directly relevant to PCOS pathophysiology.

SURMOUNT-1 and the next generation

Tirzepatide, which activates both GIP and GLP-1 receptors, was studied in SURMOUNT-1 (Jastreboff et al., NEJM 2022) in 2,539 adults with obesity. At the 15 mg dose, mean weight loss reached 20.9% at 72 weeks. For women with severe PCOS-related obesity (BMI >35) tirzepatide is increasingly the agent of choice, available in India since March 2025 as Mounjaro®. A separate tirzepatide page walks through the trial in detail.

What this means in practice

GLP-1s are not a PCOS cure. They are a metabolic tool that resolves the insulin resistance that drives most PCOS weight gain, and through that, often restores ovulation and reduces androgen excess. They do not replace lifestyle change, and they are contraindicated in women trying to conceive within the next two months. Your AIIMS-trained doctor will sequence treatment around your stage of life: a short course for fertility preparation, a longer course for metabolic control, or a maintenance dose alongside inositol or metformin. For details on the medication itself, see our pages on semaglutide and tirzepatide. Two practical companions for PCOS patients starting a GLP-1: a vegetarian and Jain protein guide (the protein-target work matters even more when insulin resistance is in play), and which blood tests to run before and during treatment, including the B12, vitamin D and ferritin markers that often run low.

  1. Jensterle M, Kravos NA, Goričar K, Janež A. Short-term efectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord. 2017;17:5.
  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989–1002.
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.